Adhesive mixture for transdermal delivery of highly plasticizing drugs
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/10
A61K-047/32
A61L-037/00
A61L-015/24
A61L-015/16
A61M-037/00
출원번호
US-0754909
(2001-01-05)
발명자
/ 주소
Govil,Sharad K.
Weimann,Ludwig J.
출원인 / 주소
Mylan Technologies, Inc.
대리인 / 주소
Lerner, David, Littenberg, Krumholz &
인용정보
피인용 횟수 :
8인용 특허 :
33
초록
Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs.
대표청구항▼
The invention claimed is: 1. A therapeutic adhesive formulation comprising: between about 65% and about 97%, by weight, of an acrylic polymeric adhesive which includes between about 40% and about 90% of a C4-C12 alkyl acrylate, between about 10% and about 40% by weight of a C1-C4 alkyl acrylare har
The invention claimed is: 1. A therapeutic adhesive formulation comprising: between about 65% and about 97%, by weight, of an acrylic polymeric adhesive which includes between about 40% and about 90% of a C4-C12 alkyl acrylate, between about 10% and about 40% by weight of a C1-C4 alkyl acrylare hardening monomer; between about 1% and about 20% by weight of a monomer which provides functional groups for crosslinking; and a crosslinking agent; and between about 3% and about 35% by weight, based on the weight of said mixture, of a highly plasticizing drug. 2. The therapeutic adhesive formulation of claim 1 wherein said C4-C12 alkyl acrylare is selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, n-decyl, n-nonyl, 2 ethyoctyl, isooctyl and dodecyl-acrylate. 3. The therapeutic adhesive formulation of claim 1 wherein said C4-C12 alkyl acrylate is provided in an amount of between about 60% and about 80% by weight based on the weight of the adhesive. 4. The therapeutic adhesive formulation of claim 2 wherein said C1-C4 alkyl acrylate hardening monomer is selected from the group consisting of methyl acrylate, methyl methacrylate, ethylacrylate, ethyl methacrylate, hydroxyethyl acrylate and hydroxy propyl methacrylate. 5. The therapeutic adhesive formulation of claim 1 wherein said C1-C4 alkyl acrylate hardening monomer is provided in an amount of between about 15% and about 30% by weight based on the weight of the adhesive. 6. The therapeutic adhesive formulation of claim 1 wherein said functionalizing monomer which facilitates crosslinking is selected from the group consisting of acrylic acid, hydroxy ethylacrylate, methacrylic acid and acrylamide. 7. The therapeutic adhesive formulation of claim 1 wherein said functionalizing monomer which facilitates crosslinking is provided in an amount of between about 3% and about 8% by weight based on the weight of the adhesive. 8. The therapeutic adhesive formulation of claim 1 wherein said highly plasticizing drug is selected from the group consisting of selegiline, fluoxetine, Des-methyl selegiline, tetracaine and chlorpheniramine. 9. The therapeutic adhesive formulation of claim 8 wherein said highly plasticizing drug is selegiline. 10. The therapeutic adhesive formulation of claim 1 wherein said highly plasticizing drug is provided in an amount of between about 3% and about 25% by weight of the finished adhesive& and drug mixture. 11. The therapeutic adhesive formulation of claim 10 wherein said highly plasticizing drug is provided in an amount of between about 3% and about 18% by weight of the finished adhesive and drug mixture. 12. The therapeutic adhesive formulation of claim 11 wherein said crosslinking agent is selected from the group consisting of butyl titinate, polybutyl titinate, aluminum isopropoxide, butyl titinate, aluminum zinc acetate, multivalent metals, methylol ureas and melamines. 13. The therapeutic adhesive formulation of claim 12 wherein said crosslinking agent is provided in an amount of between about 0.005% and about 2.0% based on the weight of the adhesive. 14. The therapeutic adhesive formulation of claim 1 wherein said formulation is anhydrous and substantially free of volatile solvents after drying. 15. A drug containing and releasing adhesive mixture comprising: between about 65% and about 97%, by weight of an acrylic polymeric adhesive which includes between about 60% and about 80% of a C4-C12 alkyl acrylate selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, n-decyl, n-nonyl, 2 ethyoctyl, isooctyl and dodecyl-acrylate; between about 15% and about 30% by weight of a C1-C4 alkyl acrylate hardening monomer selected front the group consisting of methyl acrylate, methyl methacrylate, ethylacrylate, ethyl methacrylate, hydroxyethyl acrylate and hydroxy propyl methacrylate; between about 1% and about 20% by weight of a functionalizing monomer which facilitates crosslinking selected from the group consisting of acrylic acid, hydroxy ethylacrylate, methacrylic acid and acrylamide; and a crosslinking agent provided in an amount of between about 0.005% and about 2.0%; and between about 3% and about 35% by weight, based on the weight of said mixture, of a highly plasticizing drug selected from the group consisting of selegiline, fluoxetine, des-methyl selegiline, tetracaine and chlorpheniramine. 16. The therapeutic adhesive formulation of claim 15 wherein said highly plasticizing drug is selegiline. 17. The therapeutic adhesive formulation of claim 15 which does not include a solvent after drying.
Mller Walter (Neuwied DEX) Czech Zbigniew (Koblenz DEX) Simon Gnter (Hillesheim DEX) Reinhard Joerg (Ehrenkirchen DEX), Basic active component-permeable pressure sensitive adhesive polymer material process of the production thereof and use.
Lee Eun Soo (Redwood City CA) Theeuwes Felix (Los Altos Hills CA) Wong Patrick S. L. (Hayward CA) Yum Su Il (Los Altos CA) Zaffaroni Alejandro (Atherton CA), Delayed onset transdermal delivery device.
Hymes Alan C. (Minnetonka MN) Ong Lincoln T. (Minnetonka MN) Persons Garry R. (Edina MN), Drug dispensing device for transdermal delivery of medicaments.
Baker Richard W. (Palo Alto CA) Santus Giancarlo (Milan CA ITX) Vintilla-Friedman Susan (Cupertino CA), Method and therapeutic system for smoking cessation.
Cormier Michel J. N. (Palo Alto CA) Ledger Philip W. (Mountain View CA) Amkraut Alfred (Palo Alto CA) Marty Jean P. (Sceaux FRX), Method for reducing sensitization or irritation in transdermal drug delivery and means therefor.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Horstmann Michael (Neuwied DEX) Herrmann Fritz (Neuwied DEX), Transdermal therapeutic system exhibiting an increased active substance flow and process for the production thereof.
Heiber Werner (Bedford Hills NY) Andriola Robert (Putnam Valley NY) Williams Paul (Fairlawn NJ) Ebert Charles (Redwood City CA), User-activated transdermal therapeutic system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.